Trial Profile
LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Galunisertib (Primary)
- Indications Advanced breast cancer; Carcinoma
- Focus Adverse reactions; Therapeutic Use
- 18 Jun 2019 Status changed from active, no longer recruiting to discontinued.
- 20 Feb 2019 Planned primary completion date changed from 1 Dec 2018 to 1 May 2019.
- 28 Feb 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Dec 2018.